Profund Advisors
XERS icon

Profund Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Profund Advisors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.94M Buy
202,547
+169,836
+519% +$1.43M 0.06% 209
2026
Q2 		$259K Sell
32,711
-8,422
-20% -$53.8K 0.01% 899
2026
Q1 		$239K Buy
41,133
+2,186
+6% +$14.5K 0.01% 916
2025
Q4 		$306K Buy
38,947
+12,383
+47% +$97.5K 0.01% 859
2025
Q3 		$216K Sell
26,564
-15,516
-37% -$103K 0.01% 937
2025
Q2 		$197K Buy
42,080
+21,888
+108% +$100K 0.01% 911
2025
Q1 		$111K Sell
20,192
-2,777
-12% -$11.2K ﹤0.01% 945
2024
Q4 		$77.9K Buy
22,969
+227
+1% +$730 ﹤0.01% 1084
2024
Q3 		$64.8K Sell
22,742
-1,978
-8% -$5.08K ﹤0.01% 1125
2024
Q2 		$55.6K Sell
24,720
-3,655
-13% -$7.37K ﹤0.01% 1065
2024
Q1 		$62.7K Buy
+28,375
New +$73.4K ﹤0.01% 1140

Other funds holding XERS

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return
Vilga Financial Planning
Vilga Financial Planning Fair Lawn, New Jersey $168M AUM 23.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
DMKJ
David M. Knott Jr $183M AUM 73.23% 1-Year Est. Return

Profund Advisors's XERS Position: Q3 2026 in Review

Profund Advisors increased its Xeris Biopharma Holdings (XERS) stake by 519% in Q3 2026, buying an estimated $1.43M and bringing the position to 202,547 shares worth $1.94M. The position accounts for 0.06% of the portfolio, ranked #209.

Profund Advisors first reported a position in XERS in Q1 2024 and has held it in 11 quarters since. 137 funds tracked by Wall St. Rank hold XERS as of Q3 2026.

  • Profund Advisors held 202,547 shares of Xeris Biopharma Holdings worth $1.94M as of Q3 2026.
  • Profund Advisors bought 169,836 Xeris Biopharma Holdings shares in Q3 2026, an estimated $1.43M.
  • Xeris Biopharma Holdings made up 0.06% of Profund Advisors's portfolio in Q3 2026, its #209 holding.
  • Profund Advisors first reported a position in Xeris Biopharma Holdings in Q1 2024 and has held it in 11 quarters since.
  • 137 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2026.

Based on Profund Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.